Curis down after FDA places lymphoma drug trial on partial clinical hold

Curis

11/04/2022 17:07

(Updates)
    ** Curis Inc  CRIS.O  down as much as 6% to $1.35 during
market hours on Monday
    ** Cancer drug developer says the U.S. Food and Drug
Administration has placed a partial clinical hold on another
early-to-mid stage study of its drug emavusertib  urn:newsml:reuters.com:*:nPn9WbyxPa
    ** CRIS was testing emavusertib as a treatment for B-cell
lymphoma, a cancer of the lymph system
    ** Notice extends partial hold across both studies of
emavusertib, after last week's partial clinical hold on CRIS's
leukemia trial  urn:newsml:reuters.com:*:nL3N2W21O7
    ** Co on Monday says current study participants receiving
drug treatment may continue after being reconsented
    ** Stock trading below 30 on the relative strength index
(RSI) for sixth straight trading session signaling an oversold
stock; RSI is a technical indicator on which a score of 70 or
above indicates overbought conditions, while 30 or below signals
oversold
    ** CRIS down nearly 70%, as of last close

 (Reporting by Mehnaz Yasmin in Bengaluru)
 ((Mehnaz.Yasmin@thomsonreuters.com))